Onconetix Inc

Onconetix’s board reshuffle: new chairman Sammy Dorf, new director Josh Epstein, and fresh leadership amid financial turbulence – still advancing oncology therapeutics.

Onconetix’s new CMO and R&D chief boost ONC010’s clinical trajectory, accelerating oncology drug development and regulatory readiness.

Onco‑Innovations expands in Australia, partnering with RDI Partners and forming a local subsidiary to fast‑track Phase I oncology trials while leveraging 43.5% R&D tax credits.

Onconetix, Inc. is a commercial-stage biotechnology company dedicated to advancing oncology and bringing innovative solutions to cancer treatment, offering hope to millions of patients and their families.

Onconetix Inc. and Ocuvex Therapeutics have announced a definitive merger agreement, combining their expertise in oncology and ophthalmic therapeutics to create a new entity with enhanced research capabilities and a broader product portfolio.

Onconetix Inc, a biotech firm specializing in oncology, faces financial struggles but its strategic positioning in the sector offers potential for a comeback, pending effective navigation of its financial hurdles.